OMER - Omeros Corporation

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
19.56
+0.55 (+2.89%)
At close: 4:00PM EST

19.56 0.00 (0.01%)
After hours: 5:17PM EST

Stock chart is not supported by your current browser
Previous Close19.01
Open19.10
Bid18.80 x 200
Ask24.00 x 700
Day's Range18.90 - 19.80
52 Week Range8.71 - 27.09
Volume825,931
Avg. Volume890,410
Market Cap938.954M
Beta3.56
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here's Why Omeros Corporation Is Gaining More Ground Today
    Motley Fool3 days ago

    Here's Why Omeros Corporation Is Gaining More Ground Today

    Pediatric exclusivity is a bigger deal than you might expect for a drug used during cataract surgeries.

  • Benzinga4 days ago

    Omeros' OMIDRIA Eye Drop OK'ed For Pediatric Use

    Omeros Corporation (NASDAQ: OMER ) shares are trading higher Tuesday after the commercial-stage biopharma company announced FDA approval for its supplemental new drug application, or sNDA, for OMIDRIA, ...

  • Omeros Earns Relative Strength Rating Upgrade
    Investor's Business Daily15 days ago

    Omeros Earns Relative Strength Rating Upgrade

    Omeros sees its Relative Strength Rating enter the elite 90-plus level.

  • Why Omeros Corporation Is the Best Buy in Biotech Right Now
    Motley Fool18 days ago

    Why Omeros Corporation Is the Best Buy in Biotech Right Now

    This overlooked small-cap biotech stock has two well-lit paths to glory, but you only need to pay for one.

  • Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 27, 2017
    Capital Cube19 days ago

    Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 27, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Omeros Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of OMER earnings conference call or presentation 9-Nov-17 9:30pm GMT

    Q3 2017 Omeros Corp Earnings Call

  • Capital Cube28 days ago

    Omeros Corp. – Value Analysis (NASDAQ:OMER) : November 17, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Omeros Corp. a score of 36. Our analysis is based on comparing Omeros Corp. with the following peers – Genetic Technologies Limited Sponsored ADR, BioTime, Inc., Acura Pharmaceuticals, Inc., Johnson & Johnson, Pfizer Inc., DURECT Corporation, Akorn, Inc. and Pain Therapeutics, Inc. (GENE-US, BTX-US, ACUR-US, JNJ-US, PFE-US, ... Read more (Read more...)

  • Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017
    Capital Cubelast month

    Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : November 16, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Omeros Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • TheStreet.comlast month

    5 Small Biotechs Receive Shots in the Arm

    Favorable quarterly results and FDA drug approvals should help lift these five names.

  • This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?
    Investor's Business Dailylast month

    This Biotech Just Rose By A Third On Its Earnings — But Is It In Trouble?

    Omeros rocketed to a month-high Friday after revenue from eye-surgery drug Omidria beat its typical summertime weakness.

  • SmarterAnalystlast month

    Omeros Story Continues to Get Better, but Reimbursement Risk Remains

    The fundamentals behind Omeros' (NASDAQ:OMER) eye drug Omidria continue to get better, but Cantor analyst Elemer Piros believes the company still needs to remove the uncertainty around the expiration of pass-through reimbursement.

  • This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
    Motley Foollast month

    This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today

    This company took important steps forward last quarter to continue growing.

  • Benzingalast month

    Can Omeros Top-Line Growth Continue?

    Omeros Corporation (NASDAQ: OMER ) shares are on a tear, the catalyst being the release of its third-quarter results. The Analyst Cantor Fitzgerald's Elemer Piros, Ph.D, reviewed Omeros' quarterly results. ...

  • MarketWatchlast month

    Omeros shares surge 17% after Q3 revenue beat

    Omeros Corp. shares rose 17% in premarket trade Friday after the company reported a third-quarter revenue beat and a narrower-than-expected profit loss. The company reported a loss of $7.48 million, or ...

  • SmarterAnalystlast month

    Omeros Corporation (OMER) Shares Soar Following Strong Quarter

    Omeros Corporation (NASDAQ:OMER) shares are on fire this evening, rising nearly 11%, after the drug maker reported better-than-expected 3Q Omidria sales. 3Q 2017 total and OMIDRIA® revenues were $21.7 million. Revenues from OMIDRIA sales rose 26 percent from 2Q 2017 and 92 percent from the prior year’s third quarter.

  • Associated Presslast month

    Omeros reports 3Q loss

    On a per-share basis, the Seattle-based company said it had a loss of 16 cents. Losses, adjusted for non-recurring costs, came to 7 cents per share. The drug developer posted revenue of $21.7 million in ...

  • Omeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgA
    SmarterAnalystlast month

    Omeros Corporation (OMER): Extended Follow-Up Data Evaluating OMS721 Shows Improvement in Patients with IgA

    Omeros Corporation (NASDAQ:OMER) announced that extended follow-up data from patients with immunoglobulin A (IgA) nephropathy treated with OMS721 were presented on November 4, 2017 at the American Society of Nephrology (ASN) Meetingin New Orleans. OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. During the Phase 2 clinical trial, which consisted of 12 weeks of treatment and 6 weeks of follow-up, all patients with IgA nephropathy demonstrated clinically meaningful improvement in proteinuria.

  • Capital Cubelast month

    ETFs with exposure to Omeros Corp. : November 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Omeros Corporation: Additional Positive Data in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
    SmarterAnalyst2 months ago

    Omeros Corporation: Additional Positive Data in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

    Omeros Corporation (NASDAQ:OMER) announced further positive data from its ongoing Phase 2 study of OMS721 evaluating patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA). Initial positive data from this study have been presented at the 2017 combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT). To be eligible for enrollment, HCT-TMA patients are required to be adults with post-transplant TMA persisting at least two weeks following calcineurin inhibitor modification (conservative treatment).

  • Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
    Zacks2 months ago

    Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU

    Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.

  • Omeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting
    SmarterAnalyst2 months ago

    Omeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting

    Omeros Corporation (NASDAQ:OMER) announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft-versus-host disease (GvHD), which both resolved following OMS721 treatment. This case was presented this morning at the European Society for Blood and Marrow Transplantation (EBMT) Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT in Granada, Spain. The presentation, “Effective Treatment of GvHD-Associated Transplant-Associated Microangiopathy with a Novel Inhibitor of the Lectin Pathway of Complement,” was made by Chiara Caprioli, M.D. of the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, in Bergamo, Italy.

  • Capital Cube2 months ago

    ETFs with exposure to Omeros Corp. : October 18, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • What You Must Know About Omeros Corporation’s (OMER) Risks
    Simply Wall St.2 months ago

    What You Must Know About Omeros Corporation’s (OMER) Risks

    If you are a shareholder in Omeros Corporation’s (NASDAQ:OMER), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...

  • MarketWatch2 months ago

    Omeros shares surge 10% after settlement with Endo delays generic to 2032

    Omeros Corporation shares surged as much as 10% in morning trade Thursday, before paring some gains, after the company announced a settlement with Endo International PLC's Par Pharmaceutical Inc. that ...

  • Capital Cube2 months ago

    ETFs with exposure to Omeros Corp. : October 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Omeros Corp. Here are 5 ETFs with the largest exposure to OMER-US. Comparing the performance and risk of Omeros Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)